vs
Ameriprise Financial（AMP）与美敦力（MDT）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是Ameriprise Financial的1.8倍（$9.0B vs $4.9B），Ameriprise Financial净利率更高（18.7% vs 15.3%，领先3.4%），Ameriprise Financial同比增速更快（9.0% vs 6.6%），过去两年Ameriprise Financial的营收复合增速更高（5.5% vs 5.3%）
美国金融服务商Ameriprise Financial面向美国及全球其他地区的个人与机构客户提供多元化金融产品及服务，下设顾问与财富管理、资产管理、退休与保障解决方案、企业及其他四大业务板块，可满足客户财务规划、投资咨询、经纪服务等多方面需求。
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
AMP vs MDT — 直观对比
营收规模更大
MDT
是对方的1.8倍
$4.9B
营收增速更快
AMP
高出2.4%
6.6%
净利率更高
AMP
高出3.4%
15.3%
两年增速更快
AMP
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $4.9B | $9.0B |
| 净利润 | $915.0M | $1.4B |
| 毛利率 | — | 65.8% |
| 营业利润率 | — | 18.8% |
| 净利率 | 18.7% | 15.3% |
| 营收同比 | 9.0% | 6.6% |
| 净利润同比 | 57.0% | 8.2% |
| 每股收益（稀释后） | — | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPMDT
| Q1 26 | $4.9B | — | ||
| Q4 25 | $5.0B | $9.0B | ||
| Q3 25 | $4.9B | $8.6B | ||
| Q2 25 | $4.5B | $8.9B | ||
| Q1 25 | $4.5B | $8.3B | ||
| Q4 24 | $4.6B | $8.4B | ||
| Q3 24 | $4.6B | $7.9B | ||
| Q2 24 | $4.4B | $8.6B |
净利润AMPMDT
| Q1 26 | $915.0M | — | ||
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $912.0M | $1.0B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $583.0M | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $511.0M | $1.0B | ||
| Q2 24 | $829.0M | $654.0M |
毛利率AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | — | 65.8% | ||
| Q3 25 | — | 65.0% | ||
| Q2 25 | — | 64.8% | ||
| Q1 25 | — | 66.5% | ||
| Q4 24 | — | 64.9% | ||
| Q3 24 | — | 65.1% | ||
| Q2 24 | — | 64.5% |
营业利润率AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | 25.6% | 18.8% | ||
| Q3 25 | 24.0% | 16.8% | ||
| Q2 25 | 30.1% | 16.1% | ||
| Q1 25 | 15.3% | 19.9% | ||
| Q4 24 | 29.1% | 19.0% | ||
| Q3 24 | 14.1% | 16.1% | ||
| Q2 24 | 23.9% | 12.3% |
净利率AMPMDT
| Q1 26 | 18.7% | — | ||
| Q4 25 | 20.0% | 15.3% | ||
| Q3 25 | 18.6% | 12.1% | ||
| Q2 25 | 23.6% | 11.8% | ||
| Q1 25 | 13.0% | 15.6% | ||
| Q4 24 | 23.0% | 15.1% | ||
| Q3 24 | 11.2% | 13.2% | ||
| Q2 24 | 18.9% | 7.6% |
每股收益（稀释后）AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | $10.39 | $1.07 | ||
| Q3 25 | $9.33 | $0.81 | ||
| Q2 25 | $10.73 | $0.81 | ||
| Q1 25 | $5.83 | $1.01 | ||
| Q4 24 | $10.57 | $0.99 | ||
| Q3 24 | $5.00 | $0.80 | ||
| Q2 24 | $8.02 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3B | $8.3B |
| 总债务越低越好 | $3.3B | $27.7B |
| 股东权益账面价值 | $355.9B | $48.7B |
| 总资产 | $184.4B | $91.3B |
| 负债/权益比越低杠杆越低 | 0.01× | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资AMPMDT
| Q1 26 | $8.3B | — | ||
| Q4 25 | — | $8.3B | ||
| Q3 25 | — | $8.1B | ||
| Q2 25 | — | $9.0B | ||
| Q1 25 | — | $7.9B | ||
| Q4 24 | — | $8.0B | ||
| Q3 24 | — | $7.8B | ||
| Q2 24 | — | $8.0B |
总债务AMPMDT
| Q1 26 | $3.3B | — | ||
| Q4 25 | — | $27.7B | ||
| Q3 25 | — | $26.2B | ||
| Q2 25 | — | $25.6B | ||
| Q1 25 | — | $24.0B | ||
| Q4 24 | — | $24.6B | ||
| Q3 24 | — | $26.3B | ||
| Q2 24 | — | $23.9B |
股东权益AMPMDT
| Q1 26 | $355.9B | — | ||
| Q4 25 | $6.5B | $48.7B | ||
| Q3 25 | $6.5B | $47.9B | ||
| Q2 25 | $6.1B | $48.0B | ||
| Q1 25 | $5.4B | $49.4B | ||
| Q4 24 | $5.2B | $48.5B | ||
| Q3 24 | $5.7B | $47.9B | ||
| Q2 24 | $5.0B | $50.2B |
总资产AMPMDT
| Q1 26 | $184.4B | — | ||
| Q4 25 | $190.9B | $91.3B | ||
| Q3 25 | $190.1B | $91.0B | ||
| Q2 25 | $184.9B | $91.7B | ||
| Q1 25 | $179.1B | $90.0B | ||
| Q4 24 | $181.4B | $90.0B | ||
| Q3 24 | $186.0B | $89.7B | ||
| Q2 24 | $179.7B | $90.0B |
负债/权益比AMPMDT
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | 0.57× | ||
| Q3 25 | — | 0.55× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.55× | ||
| Q2 24 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $925.0M |
| 自由现金流经营现金流 - 资本支出 | — | $457.0M |
| 自由现金流率自由现金流/营收 | — | 5.1% |
| 资本支出强度资本支出/营收 | — | 5.2% |
| 现金转化率经营现金流/净利润 | — | 0.67× |
| 过去12个月自由现金流最近4个季度 | — | $5.2B |
8季度趋势，按日历期对齐
经营现金流AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | $925.0M | ||
| Q3 25 | $2.2B | $1.1B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $1.7B | $2.6B | ||
| Q4 24 | $383.0M | $958.0M | ||
| Q3 24 | $3.0B | $986.0M | ||
| Q2 24 | $1.7B | $2.8B |
自由现金流AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $457.0M | ||
| Q3 25 | $2.2B | $584.0M | ||
| Q2 25 | $1.7B | $2.1B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $325.0M | $554.0M | ||
| Q3 24 | $3.0B | $466.0M | ||
| Q2 24 | $1.7B | $2.4B |
自由现金流率AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | 52.0% | 5.1% | ||
| Q3 25 | 44.1% | 6.8% | ||
| Q2 25 | 38.4% | 23.2% | ||
| Q1 25 | 36.8% | 25.3% | ||
| Q4 24 | 7.0% | 6.6% | ||
| Q3 24 | 65.8% | 5.9% | ||
| Q2 24 | 38.8% | 27.4% |
资本支出强度AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 5.2% | ||
| Q3 25 | 0.9% | 5.9% | ||
| Q2 25 | 0.8% | 5.1% | ||
| Q1 25 | 0.8% | 5.7% | ||
| Q4 24 | 1.2% | 4.8% | ||
| Q3 24 | 1.1% | 6.6% | ||
| Q2 24 | 0.4% | 5.0% |
现金转化率AMPMDT
| Q1 26 | — | — | ||
| Q4 25 | 2.65× | 0.67× | ||
| Q3 25 | 2.42× | 1.05× | ||
| Q2 25 | 1.66× | 2.39× | ||
| Q1 25 | 2.89× | 1.99× | ||
| Q4 24 | 0.36× | 0.75× | ||
| Q3 24 | 5.96× | 0.95× | ||
| Q2 24 | 2.07× | 4.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMP
| Management and financial advice fees | $2.9B | 60% |
| Other | $872.0M | 18% |
| Distribution fees | $563.0M | 12% |
| Premiums, policy and contract charges | $341.0M | 7% |
| Other revenues | $166.0M | 3% |
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
